{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T18:03:51Z","timestamp":1764785031863,"version":"3.40.5"},"reference-count":51,"publisher":"Public Library of Science (PLoS)","issue":"1","license":[{"start":{"date-parts":[[2023,1,12]],"date-time":"2023-01-12T00:00:00Z","timestamp":1673481600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Background<\/jats:title>\n<jats:p>SARS-CoV-2 invades human cells and leads to COVID-19 by direct associating with angiotensin converting enzyme 2 (ACE2) receptors, the level of which may be increased by treatment with angiotensin-converting enzyme inhibitors (ACEIs) and\/or angiotensin receptor blockers (ARBs). This meta-analysis aimed to explore the impact of ACEI\/ARB treatment on the clinical outcomes of patients with COVID-19 infections among population in the East-Asia region.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Methods<\/jats:title>\n<jats:p>We collected clinical data published from January 2000 to May 2022 in the English databases including PubMed, Embase, and the Cochrane Library. Two reviewers independently screened and identified studies that met the prespecified criteria. Review Manager 5.3 software was used to perform the meta-analysis.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Results<\/jats:title>\n<jats:p>A total of 28 articles were included in this analysis. The results showed that patients who were prescribed with ACEI\/ARB had a shorter duration of hospital stay [MD = -2.37, 95%CI (-3.59, -1.14), P = 0.000 2] and a lower mortality rate [OR = 0.61, 95% CI (0.52, 0.70), P&lt;0.000 01] than patients who were not on ACEI\/ARB. Furthermore, there was no statistically significant difference in disease severity [OR = 0.99, 95% CI (0.83, 1.17), P = 0.90] between individuals receiving ACEI\/ARB or not.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Conclusions<\/jats:title>\n<jats:p>This meta-analysis suggested that the use of ACEI\/ARB was not associated with adverse clinical outcomes in East-Asian Covid-19 patients and a reduced mortality and shorter duration of hospital stay among East-Asian population (especially for female subjects) was found. Thus, ACEI\/ARB should be continued in patients infected by Covid-19.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0280280","type":"journal-article","created":{"date-parts":[[2023,1,12]],"date-time":"2023-01-12T18:35:42Z","timestamp":1673548542000},"page":"e0280280","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":14,"title":["Systematic review and meta-analysis of the clinical outcomes of ACEI\/ARB in East-Asian patients with COVID-19"],"prefix":"10.1371","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6944-844X","authenticated-orcid":true,"given":"Nancy Xurui","family":"Huang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qi","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fang","family":"Fang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bryan P.","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John E.","family":"Sanderson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2023,1,12]]},"reference":[{"key":"pone.0280280.ref001","first-page":"71","article-title":"World Health Organization declares global emergency: A review of the 2019 novel coronavirus (COVID-19)","volume":"76","author":"C Sohrabi","journal-title":"Int J Surg. 2020"},{"key":"pone.0280280.ref002","unstructured":"WHO coronavirus disease (COVID-19) dashboard 2020 [cited 2022 1 May]. https:\/\/covid19.who.int\/."},{"issue":"1","key":"pone.0280280.ref003","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/s41371-020-0387-4","article-title":"Covid-19 and the cardiovascular system: a comprehensive review","volume":"35","author":"RB Azevedo","year":"2021","journal-title":"J Hum Hypertens"},{"issue":"7","key":"pone.0280280.ref004","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1001\/jamacardio.2020.0950","article-title":"Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan","volume":"5","author":"S Shi","year":"2020","journal-title":"China. JAMA Cardiol"},{"issue":"7","key":"pone.0280280.ref005","doi-asserted-by":"crossref","DOI":"10.1111\/acel.13168","article-title":"Individual variation of the SARS-CoV-2 receptor ACE2 gene expression and regulation","volume":"19","author":"J Chen","year":"2020","journal-title":"Aging Cell"},{"key":"pone.0280280.ref006","doi-asserted-by":"crossref","first-page":"b2700","DOI":"10.1136\/bmj.b2700","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration","volume":"339","author":"A Liberati","year":"2009","journal-title":"Bmj"},{"key":"pone.0280280.ref007","unstructured":"Wells GA SB, O\u2019Connell D, Peterson J, Welch V, Losos M, Tugwell P. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses: The Ottawa Hospital Research Institute; 2019 [cited 2022 February 1]. http:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp."},{"issue":"3","key":"pone.0280280.ref008","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1053\/j.gastro.2020.05.034","article-title":"Associations Between Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blocker Use, Gastrointestinal Symptoms, and Mortality Among Patients With COVID-19","volume":"159","author":"ND Tan","year":"2020","journal-title":"Gastroenterology"},{"issue":"7","key":"pone.0280280.ref009","doi-asserted-by":"crossref","first-page":"430","DOI":"10.21037\/atm.2020.03.229","article-title":"The effect of RAS blockers on the clinical characteristics of COVID-19 patients with hypertension","volume":"8","author":"Z Huang","year":"2020","journal-title":"Ann Transl Med"},{"issue":"2","key":"pone.0280280.ref010","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1536\/ihj.20-323","article-title":"Hypertension in Patients Hospitalized with COVID-19 in Wuhan, China","volume":"62","author":"Y Zhang","year":"2021","journal-title":"Int Heart J"},{"issue":"8","key":"pone.0280280.ref011","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1111\/crj.13382","article-title":"Predictors of fatal outcomes among hospitalized COVID-19 patients with pre-existing hypertension in China","volume":"15","author":"T Wang","year":"2021","journal-title":"Clin Respir J"},{"issue":"1","key":"pone.0280280.ref012","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1186\/s12879-021-05821-5","article-title":"Angiotensin-converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARBs) may be safe for COVID-19 patients","volume":"21","author":"W Wang","year":"2021","journal-title":"BMC Infect Dis"},{"issue":"6","key":"pone.0280280.ref013","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/j.jinf.2020.05.056","article-title":"COVID-19 is more severe in patients with hypertension; ACEI\/ARB treatment does not influence clinical severity and outcome","volume":"81","author":"J Hu","year":"2020","journal-title":"J Infect"},{"issue":"1","key":"pone.0280280.ref014","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1161\/HYPERTENSIONAHA.120.15143","article-title":"Effects of Angiotensin II Receptor Blockers and ACE (Angiotensin-Converting Enzyme) Inhibitors on Virus Infection, Inflammatory Status, and Clinical Outcomes in Patients with COVID-19 and Hypertension: A Single-Center Retrospective Study","volume":"76","author":"G Yang","year":"2020","journal-title":"Hypertension"},{"issue":"5","key":"pone.0280280.ref015","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/j.jinf.2020.08.014","article-title":"In-hospital use of ACEI\/ARB is associated with lower risk of mortality and critic illness in COVID-19 patients with hypertension","volume":"81","author":"Y Yuan","year":"2020","journal-title":"J Infect"},{"issue":"7","key":"pone.0280280.ref016","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.2337\/dc20-0660","article-title":"Clinical Characteristics and Outcomes of Patients With Diabetes and COVID-19 in Association With Glucose-Lowering Medication","volume":"43","author":"Y Chen","year":"2020","journal-title":"Diabetes Care"},{"issue":"22","key":"pone.0280280.ref017","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1093\/eurheartj\/ehaa433","article-title":"Association of hypertension and antihypertensive treatment with COVID-19 mortality: a retrospective observational study","volume":"41","author":"C Gao","year":"2020","journal-title":"Eur Heart J"},{"issue":"7","key":"pone.0280280.ref018","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1001\/jamacardio.2020.1624","article-title":"Association of Renin-Angiotensin System Inhibitors With Severity or Risk of Death in Patients With Hypertension Hospitalized for Coronavirus Disease 2019 (COVID-19) Infection in Wuhan, China","volume":"5","author":"J Li","year":"2020","journal-title":"JAMA Cardiol"},{"issue":"1","key":"pone.0280280.ref019","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.jaci.2020.04.006","article-title":"Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan","volume":"146","author":"X Li","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"pone.0280280.ref020","first-page":"20039586","article-title":"Anti-hypertensive Angiotensin II receptor blockers associated to mitigation of disease severity in elderly COVID-19 patients","volume":"20","author":"Y Liu","year":"2020","journal-title":"medRxiv"},{"issue":"1","key":"pone.0280280.ref021","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1080\/22221751.2020.1746200","article-title":"Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension","volume":"9","author":"J Meng","year":"2020","journal-title":"Emerg Microbes Infect"},{"issue":"4","key":"pone.0280280.ref022","article-title":"Effects Of ARBs And ACEIs On Virus Infection, Inflammatory Status And Clinical Outcomes In COVID-19 Patients With Hypertension: A Single Center Retrospective Study","volume":"76","author":"ZT Guang Yang","year":"2020","journal-title":"Hypertension"},{"key":"pone.0280280.ref023","doi-asserted-by":"crossref","first-page":"710946","DOI":"10.3389\/fcvm.2021.710946","article-title":"Impact of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers on the Inflammatory Response and Viral Clearance in COVID-19 Patients","volume":"8","author":"L Huang","year":"2021","journal-title":"Front Cardiovasc Med"},{"issue":"3","key":"pone.0280280.ref024","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1161\/HYPERTENSIONAHA.120.15289","article-title":"Clinical Features of COVID-19 in Patients With Essential Hypertension and the Impacts of Renin-angiotensin-aldosterone System Inhibitors on the Prognosis of COVID-19 Patients","volume":"76","author":"W Pan","year":"2020","journal-title":"Hypertension"},{"issue":"11","key":"pone.0280280.ref025","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1038\/s41440-020-00535-8","article-title":"Renin-angiotensin system inhibitors and the severity of coronavirus disease 2019 in Kanagawa, Japan: a retrospective cohort study","volume":"43","author":"Y Matsuzawa","year":"2020","journal-title":"Hypertens Res"},{"issue":"3","key":"pone.0280280.ref026","doi-asserted-by":"crossref","first-page":"e0248058","DOI":"10.1371\/journal.pone.0248058","article-title":"Effect of renin-angiotensin-aldosterone system inhibitors on Covid-19 patients in Korea","volume":"16","author":"J Park","year":"2021","journal-title":"PLoS One"},{"key":"pone.0280280.ref027","doi-asserted-by":"crossref","first-page":"e2021004","DOI":"10.4178\/epih.e2021004","article-title":"Clinical outcomes of COVID-19 following the use of angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers among patients with hypertension in Korea: a nationwide study","volume":"43","author":"JH Kim","year":"2021","journal-title":"Epidemiol Health"},{"issue":"5","key":"pone.0280280.ref028","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1007\/s11427-020-1813-0","article-title":"Angiotensin converting enzyme inhibitors and angiotensin receptor blockers improved the outcome of patients with severe COVID-19 and hypertension","volume":"64","author":"X Meng","year":"2021","journal-title":"Sci China Life Sci"},{"key":"pone.0280280.ref029","first-page":"1","article-title":"Renin-angiotensin system inhibitor is associated with the reduced risk of all-cause mortality in COVID-19 among patients with\/without hypertension","author":"HY Wang","year":"2021","journal-title":"Front Med"},{"issue":"12","key":"pone.0280280.ref030","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1161\/CIRCRESAHA.120.317134","article-title":"Association of Inpatient Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Mortality Among Patients With Hypertension Hospitalized With COVID-19","volume":"126","author":"P Zhang","year":"2020","journal-title":"Circ Res"},{"issue":"3","key":"pone.0280280.ref031","doi-asserted-by":"crossref","first-page":"430","DOI":"10.4093\/dmj.2020.0279","article-title":"Use of Renin-Angiotensin-Aldosterone System Inhibitors and Severe COVID-19 Outcomes in Patients with Hypertension: A Nationwide Cohort Study","volume":"45","author":"JH Bae","year":"2021","journal-title":"Diabetes Metab J"},{"issue":"11","key":"pone.0280280.ref032","doi-asserted-by":"crossref","first-page":"ofaa519","DOI":"10.1093\/ofid\/ofaa519","article-title":"Effects of Recent Use of Renin-Angiotensin System Inhibitors on Mortality of Patients With Coronavirus Disease 2019","volume":"7","author":"S Bae","year":"2020","journal-title":"Open Forum Infect Dis"},{"issue":"9","key":"pone.0280280.ref033","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1007\/s10072-020-04541-z","article-title":"Neurological diseases as mortality predictive factors for patients with COVID-19: a retrospective cohort study","volume":"41","author":"JM Hwang","year":"2020","journal-title":"Neurological Sciences"},{"issue":"1","key":"pone.0280280.ref034","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s40885-021-00168-0","article-title":"Hypertension, renin-angiotensin-aldosterone-system-blocking agents, and COVID-19","volume":"27","author":"SH Kang","year":"2021","journal-title":"Clin Hypertens"},{"issue":"Suppl 1","key":"pone.0280280.ref035","doi-asserted-by":"crossref","first-page":"S123","DOI":"10.3904\/kjim.2020.390","article-title":"Effects of renin-angiotensin system blockers on the risk and outcomes of severe acute respiratory syndrome coronavirus 2 infection in patients with hypertension","volume":"36","author":"J Lee","year":"2021","journal-title":"Korean J Intern Med"},{"issue":"Suppl 1","key":"pone.0280280.ref036","doi-asserted-by":"crossref","first-page":"S114","DOI":"10.3904\/kjim.2020.380","article-title":"Update on association between exposure to renin-angiotensin-aldosterone system inhibitors and coronavirus disease 2019 in South Korea","volume":"36","author":"J Seo","year":"2021","journal-title":"Korean J Intern Med"},{"issue":"11","key":"pone.0280280.ref037","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1164\/rccm.202002-0445OC","article-title":"COVID-19 with Different Severities: A Multicenter Study of Clinical Features","volume":"201","author":"Y Feng","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"pone.0280280.ref038","unstructured":"The International Society of Hypertension. A statement from the International Society of Hypertension on COVID-19. https:\/\/ish-world.com\/news\/a\/A-statement-from-the-International-Society-of-Hypertension-on-COVID-19\/."},{"issue":"5","key":"pone.0280280.ref039","article-title":"Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis","volume":"55","author":"WJ Guan","year":"2020","journal-title":"Eur Respir J"},{"issue":"5","key":"pone.0280280.ref040","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1161\/01.HYP.0000124667.34652.1a","article-title":"Upregulation of angiotensin-converting enzyme 2 after myocardial infarction by blockade of angiotensin II receptors","volume":"43","author":"Y Ishiyama","year":"2004","journal-title":"Hypertension"},{"key":"pone.0280280.ref041","article-title":"Is there a magic bullet to save COVID-19 patients? We can give it a try!","author":"A. Garami","year":"2020","journal-title":"BMJ British Medical Journal"},{"issue":"8","key":"pone.0280280.ref042","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1111\/jcmm.12573","article-title":"Perinatally administered losartan augments renal ACE2 expression but not cardiac or renal Mas receptor in spontaneously hypertensive rats","volume":"19","author":"J Klimas","year":"2015","journal-title":"J Cell Mol Med"},{"issue":"9","key":"pone.0280280.ref043","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1007\/s11255-016-1334-8","article-title":"Urinary angiotensin converting enzyme 2 is strongly related to urinary nephrin in type 2 diabetes patients","volume":"48","author":"CP Mariana","year":"2016","journal-title":"Int Urol Nephrol"},{"issue":"4","key":"pone.0280280.ref044","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1007\/s00726-014-1889-6","article-title":"Human intestine luminal ACE2 and amino acid transporter expression increased by ACE-inhibitors","volume":"47","author":"RN Vuille-dit-Bille","year":"2015","journal-title":"Amino Acids"},{"issue":"4","key":"pone.0280280.ref045","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1161\/HYPERTENSIONAHA.121.17674","article-title":"Distinct Regulation of U-ACE2 and P-ACE2 (Urinary and Plasma Angiotensin-Converting Enzyme 2) in a Japanese General Population","volume":"78","author":"M Furuhashi","year":"2021","journal-title":"Hypertension"},{"issue":"1","key":"pone.0280280.ref046","doi-asserted-by":"crossref","first-page":"5453","DOI":"10.1038\/s41467-020-19145-6","article-title":"ACE2 localizes to the respiratory cilia and is not increased by ACE inhibitors or ARBs","volume":"11","author":"IT Lee","year":"2020","journal-title":"Nat Commun"},{"key":"pone.0280280.ref047","unstructured":"Heart Failure Society of America; American College of Cardiology; American Heart Association. HFSA\/ACC\/AHA Statement Addresses Concerns Re: Using RAAS Antagonists in COVID-19- American College of Cardiology."},{"issue":"7047","key":"pone.0280280.ref048","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/nature03712","article-title":"Angiotensin-converting enzyme 2 protects from severe acute lung failure","volume":"436","author":"Y Imai","year":"2005","journal-title":"Nature"},{"issue":"25","key":"pone.0280280.ref049","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1056\/NEJMoa2008975","article-title":"Renin-Angiotensin-Aldosterone System Inhibitors and Risk of Covid-19","volume":"382","author":"HR Reynolds","year":"2020","journal-title":"N Engl J Med"},{"issue":"2","key":"pone.0280280.ref050","doi-asserted-by":"crossref","first-page":"154","DOI":"10.4266\/kjccm.2016.00976","article-title":"Effect of Renin-Angiotensin System Blockage in Patients with Acute Respiratory Distress Syndrome: A Retrospective Case Control Study","volume":"32","author":"J Kim","year":"2017","journal-title":"Korean J Crit Care Med"},{"issue":"2","key":"pone.0280280.ref051","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.116.004675","article-title":"Initiation, Continuation, or Withdrawal of Angiotensin-Converting Enzyme Inhibitors\/Angiotensin Receptor Blockers and Outcomes in Patients Hospitalized With Heart Failure With Reduced Ejection Fraction","volume":"6","author":"LG Gilstrap","year":"2017","journal-title":"J Am Heart Assoc"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0280280","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,12]],"date-time":"2023-01-12T18:36:30Z","timestamp":1673548590000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0280280"}},"subtitle":[],"editor":[{"given":"Masaki","family":"Mogi","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2023,1,12]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,1,12]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0280280","relation":{},"ISSN":["1932-6203"],"issn-type":[{"type":"electronic","value":"1932-6203"}],"subject":[],"published":{"date-parts":[[2023,1,12]]}}}